CA3182105A1 - Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use - Google Patents

Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Info

Publication number
CA3182105A1
CA3182105A1 CA3182105A CA3182105A CA3182105A1 CA 3182105 A1 CA3182105 A1 CA 3182105A1 CA 3182105 A CA3182105 A CA 3182105A CA 3182105 A CA3182105 A CA 3182105A CA 3182105 A1 CA3182105 A1 CA 3182105A1
Authority
CA
Canada
Prior art keywords
methyl
pyrazol
tautomer
compound
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3182105A
Other languages
English (en)
French (fr)
Inventor
Lara C. CZABANIUK
Timothy Hopper
Jonathan B. Houze
Jane PANTELEEV
Gwenaella Rescourio
Vincent Santora
Haoxuan WANG
Ryan D. WHITE
Alice R. WONG
Yongwei Wu
Maxence BOS
John Mancuso
Ivan FRANZONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Vigil Neuroscience Inc
Original Assignee
Amgen Inc
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Vigil Neuroscience Inc filed Critical Amgen Inc
Publication of CA3182105A1 publication Critical patent/CA3182105A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3182105A 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use Pending CA3182105A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063019772P 2020-05-04 2020-05-04
US63/019,772 2020-05-04
PCT/US2021/070507 WO2021226629A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Publications (1)

Publication Number Publication Date
CA3182105A1 true CA3182105A1 (en) 2021-11-11

Family

ID=78468522

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3182105A Pending CA3182105A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Country Status (21)

Country Link
US (4) US11608344B2 (cg-RX-API-DMAC10.html)
EP (1) EP4146222A4 (cg-RX-API-DMAC10.html)
JP (2) JP7754846B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230019822A (cg-RX-API-DMAC10.html)
CN (1) CN115867284A (cg-RX-API-DMAC10.html)
AR (1) AR122010A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021266805A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022022341A2 (cg-RX-API-DMAC10.html)
CA (1) CA3182105A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022003047A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022015930A2 (cg-RX-API-DMAC10.html)
CR (1) CR20220560A (cg-RX-API-DMAC10.html)
CU (1) CU24735B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP22089527A (cg-RX-API-DMAC10.html)
IL (1) IL297833A (cg-RX-API-DMAC10.html)
JO (1) JOP20220296A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022013842A (cg-RX-API-DMAC10.html)
PE (1) PE20230846A1 (cg-RX-API-DMAC10.html)
PH (1) PH12022552949A1 (cg-RX-API-DMAC10.html)
TW (1) TW202208355A (cg-RX-API-DMAC10.html)
WO (1) WO2021226629A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
US20230082623A1 (en) * 2020-12-04 2023-03-16 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
TW202309029A (zh) * 2021-05-04 2023-03-01 美商維佳神經科學有限公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
TW202325290A (zh) * 2021-11-09 2023-07-01 美商維佳神經科學有限公司 作為骨髓細胞上表現之觸發受體２促效劑之雜環化合物及其使用方法
US20260152484A1 (en) * 2021-11-09 2026-06-04 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
EP4499693A1 (en) * 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024233848A1 (en) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CN121443608A (zh) * 2023-07-17 2026-01-30 穆纳治疗有限公司 Trem2调节剂
WO2025128848A1 (en) * 2023-12-12 2025-06-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AU2025206254A1 (en) 2024-01-04 2026-06-11 Muna Therapeutics Aps Trem2 modulators
IL328677A (en) 2024-01-04 2026-07-01 Muna Therapeutics Aps 2-Azatidinyl-7-methyl-8-oxo-6-(trifluoromethyl)-8,7-dihydropyrimido[4,5-D]pyrimidine derivatives as TREM2 modulators for the treatment of neurodegenerative diseases
WO2025157993A1 (en) * 2024-01-24 2025-07-31 Muna Therapeutics Aps Trem2 modulators
WO2026024121A1 (en) * 2024-07-25 2026-01-29 Yuhan Corporation Bicyclic fused-ring derivative or salt thereof and pharmaceutical composition including the same
WO2026077861A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026077862A1 (en) * 2024-10-07 2026-04-16 F. Hoffmann-La Roche Ag Trem2 agonists
WO2026099455A1 (en) * 2024-11-08 2026-05-15 Muna Therapeutics Aps Dihydropyrrolopyrimidinone compounds as trem2 modulators
WO2026115009A1 (en) * 2024-11-29 2026-06-04 F. Hoffmann-La Roche Ag Trem2 agonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
US3712892A (en) 1969-08-02 1973-01-23 Sumitomo Chemical Co Quinazolinone derivatives
JPH05170744A (ja) * 1991-12-25 1993-07-09 Toray Dow Corning Silicone Co Ltd 含窒素芳香族複素環式化合物のアルキル化方法
IL112235A (en) 1994-01-03 2000-06-29 Acea Pharm Inc 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them
SI1028950T1 (en) 1997-10-28 2003-08-31 Warner-Lambert Company Llc 7-substituted quinazolin-2,4-diones useful as antibacterial agents
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2004521892A (ja) 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
ES2440217T3 (es) 2002-10-04 2014-01-28 Prana Biotechnology Limited Compuestos neurológicamente activos
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
PT1673092E (pt) 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
CA2543710A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
WO2005087742A1 (en) * 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
DK1737831T3 (da) 2004-04-02 2013-08-19 Prana Biotechnology Ltd Neurologisk aktive forbindelser
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007010401A (es) * 2005-02-25 2008-02-19 Kudos Pharm Ltd Derivados de 2,4-diamino-piridopirimidina y su uso como inhbidores de mtor.
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
WO2007038331A2 (en) 2005-09-23 2007-04-05 Smithkline Beecham Corporation Novel chemical compounds
EP1996191A4 (en) 2006-03-02 2010-05-19 Glaxosmithkline Llc THIAZOLONE AS A PI3 KINASE INHIBITOR
US7855194B2 (en) * 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
JP5227321B2 (ja) 2006-08-23 2013-07-03 クドス ファーマシューティカルズ リミテッド Ｍｔｏｒ阻害剤としての２−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
BRPI0818426A2 (pt) 2007-10-15 2017-06-13 Astrazeneca Ab produto de combinação, uso de um produto de combinação, e, método para tratar câncer
US20110098267A1 (en) 2008-02-07 2011-04-28 Synta Pharmaceuticals Corporation Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
ES2617873T3 (es) 2008-10-10 2017-06-20 Vm Discovery, Inc. Composiciones y métodos para tratar trastornos de alcoholismo, dolor y otras enfermedades
JP2012520887A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102574847A (zh) 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
US20110124597A1 (en) 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
JP5993742B2 (ja) 2009-10-29 2016-09-14 ジェノスコ キナーゼ阻害剤
EP2547664B1 (de) * 2010-03-16 2016-05-04 Merck Patent GmbH Morpholinylchinazoline
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
US10260097B2 (en) * 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
EA039373B1 (ru) 2012-02-08 2022-01-19 Янссен Сайенсиз Айрлэнд Юси Производные пиперидино-пиримидина для лечения вирусных инфекций
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
PE20180316A1 (es) 2015-04-15 2018-02-09 Hoffmann La Roche Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
EP3335254B1 (de) 2015-08-11 2020-04-08 Merck Patent GmbH Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
IL307931A (en) 2016-04-15 2023-12-01 Epizyme Inc Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
CA3039124A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2018066812A1 (en) 2016-10-05 2018-04-12 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
CN109790183A (zh) 2016-12-13 2019-05-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AU2018243749A1 (en) 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
WO2018195450A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
WO2018227228A1 (en) 2017-06-13 2018-12-20 Commonwealth Scientific And Industrial Research Organisation Antiviral drugs
US20200275661A1 (en) 2017-09-26 2020-09-03 Nippon Soda Co., Ltd. Quinoline compound, and agricultural and horticultural fungicide
AU2018353150B2 (en) 2017-10-18 2024-06-06 Epizyme, Inc. Methods of using EHMT2 inhibitors in treating or preventing blood disorders
US20210213014A1 (en) 2017-10-18 2021-07-15 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
EP3966208A4 (en) 2019-05-10 2024-01-03 Antidote IP Holdings, LLC COMPOUNDS AND METHODS FOR TREATING CANCER
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
CN116322696A (zh) 2020-05-04 2023-06-23 安进公司 作为髓样细胞上表达的触发受体2激动剂的杂环化合物和使用方法
KR20230005893A (ko) 2020-05-04 2023-01-10 다케다 야쿠힌 고교 가부시키가이샤 내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체
BR112022022281A2 (pt) 2020-05-04 2023-01-03 Adama Makhteshim Ltd Misturas e composições compreendendo 5-fluoro-4-imino-3-metil- 1-tosil-3,4-dihidropirimidin-2-ona e métodos de uso das mesmas
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用
CN118633022A (zh) 2022-01-11 2024-09-10 雷杰纳荣制药公司 骨髓细胞上表达的触发受体2(trem2)变体以及其在治疗阿尔茨海默病中的用途

Also Published As

Publication number Publication date
WO2021226629A1 (en) 2021-11-11
US20240182477A1 (en) 2024-06-06
EP4146222A1 (en) 2023-03-15
CR20220560A (es) 2023-08-18
TW202208355A (zh) 2022-03-01
JP2023525035A (ja) 2023-06-14
JP2026004465A (ja) 2026-01-14
KR20230019822A (ko) 2023-02-09
US20230295170A1 (en) 2023-09-21
CU24735B1 (es) 2025-02-07
BR112022022341A2 (pt) 2023-01-10
US11912711B2 (en) 2024-02-27
CL2022003047A1 (es) 2023-07-14
EP4146222A4 (en) 2024-10-09
US11884675B2 (en) 2024-01-30
CO2022015930A2 (es) 2023-01-26
US12428425B2 (en) 2025-09-30
PH12022552949A1 (en) 2024-02-12
US20230002390A1 (en) 2023-01-05
CN115867284A (zh) 2023-03-28
US20230295169A1 (en) 2023-09-21
MX2022013842A (es) 2023-02-22
IL297833A (en) 2023-01-01
AU2021266805A1 (en) 2022-12-01
CU20220064A7 (es) 2023-06-13
PE20230846A1 (es) 2023-05-23
JOP20220296A1 (ar) 2022-11-02
JP7754846B2 (ja) 2025-10-15
ECSP22089527A (es) 2023-02-28
AR122010A1 (es) 2022-08-03
US11608344B2 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
JP7754846B2 (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物及び使用方法
CA3219215A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
CA3013618C (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
CA3182541A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2023086800A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
TW202513063A (zh) 用於治療癌症及其他適應症之稠合吡啶
WO2018066718A1 (en) Therapeutic compounds
MX2013005603A (es) Derivados de pirrolopiridina sustituidos con ciclobutilo como inhibidores de janus cinasas (jak).
CA2742320A1 (en) Pyrido[4,3-b]indoles containing rigid moieties
CA3161739A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4430022A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025136898A1 (en) Agonists of trem2 activity
CA3015166C (en) 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
WO2024233848A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025128848A1 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
IL324897A (en) Trem2 agonists
JP2024544552A (ja) ミエロイド細胞に発現するトリガー受容体２アゴニストとしてのヘテロ環化合物
TW202535376A (zh) 作為骨髓細胞上表現之觸發受體２促效劑之雜環吡啶酮化合物及使用方法
WO2024233847A2 (en) Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
AU2024294814A1 (en) Trem2 modulators
WO2023169170A1 (zh) 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
WO2026087634A1 (en) Trem2 agonists
CA3174252A1 (en) Compounds active towards nuclear receptors

Legal Events

Date Code Title Description
P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241106

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250501

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250502

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250714

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250714

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250714

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250714

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260309

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260310

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260327

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260720